Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)

NCT06805617 is registered in ClinicalTrials.gov with Glenn J. Hanna as lead sponsor.

NCT NCT06805617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06805617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers (I-MAC)
Lead sponsor
Glenn J. Hanna
Phase
Phase 2
Overall status
Recruiting
Start date
February 26, 2025
Completion date
July 1, 2027
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, advanced salivary gland carcinoma, metastatic salivary gland cancer, salivary gland cancer